<DOC>
	<DOC>NCT00511108</DOC>
	<brief_summary>A clinical study to determine the safety, efficacy and mechanism of action of sitagliptin alone and in combination with pioglitazone, in patients with type 2 diabetes mellitus who have inadequate glycemic (blood sugar) control.</brief_summary>
	<brief_title>Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patient has type 2 diabetes mellitus Male Female that is highly unlikely to become pregnant Patient is not on an antihyperglycemic agent (AHA) (hemoglobin A1c [A1C] 710%) or on oral single AHA or lowdose combination therapy (A1C 6.59.0%) Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis Patient has required insulin therapy within the past 12 weeks Patient is on or has been taking a Peroxisome ProliferatorActivated Receptorgamma (PPAR gamma) agent (i.e. Thiazolidinediones [TZDs]) within the prior 12 weeks of the screening visit.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Type 2 Diabetes Mellitus (T2DM)</keyword>
</DOC>